Fig. 2
From: In vivo mechanisms of resveratrol liposomes in targeting the TLR4/NLRP3 pathway in lung cancer
In vivo anti-tumor evaluation of resveratrol liposomes. (A) Schematic of the lung tumor model in which C57BL/6J mice were intrathoracically injected with LLC-luc cells (2 × 105 cells), and then treated with Blank Lip, Rsv, or Rsv-Lip inoculated i.p. on days 5, 8, and 11. (B) Representative images of tumor bioluminescence of tumor growth (n = 5 mice/group); (C) Photographs and (D) weight of tumors at the experimental endpoint (n = 5 mice/group); (E) Survival curves (n = 6 mice/group). Data are presented as mean ± standard deviation, n = 5 (*p < 0.05, ****p < 0.0001, ns indicates no statistically significant difference between samples).
